K Pharma,Inc. (4896.T)
JPY 756.0
(-1.82%)
JPY 756.0
(-1.82%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -3.26 Billion JPY | -144.34% |
| 2022 | -1.33 Billion JPY | -608.14% |
| 2021 | -188.78 Million JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -2.69 Billion JPY | 8.16% |
| 2024 Q1 | -2.93 Billion JPY | 10.17% |
| 2023 FY | -3.26 Billion JPY | -144.34% |
| 2023 Q4 | -3.26 Billion JPY | -70.77% |
| 2023 Q3 | -1.91 Billion JPY | 12.08% |
| 2023 Q2 | -2.17 Billion JPY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 742.75 Million JPY | 539.767% |
| PRISM BioLab Co.,LTD | -1.13 Billion JPY | -188.058% |
| GNI Group Ltd. | -17.93 Billion JPY | 81.786% |
| Linical Co., Ltd. | -4.46 Billion JPY | 26.816% |
| Trans Genic Inc. | -221.16 Million JPY | -1376.883% |
| MEDINET Co., Ltd. | -4.39 Billion JPY | 25.663% |
| Soiken Holdings Inc. | -4.79 Billion JPY | 31.808% |
| Cytori Cell Research Institute, Inc. | 1.43 Billion JPY | 327.857% |
| AnGes, Inc. | -3.79 Billion JPY | 13.991% |
| OncoTherapy Science, Inc. | -420.8 Million JPY | -676.225% |
| Nxera Pharma Co., Ltd. | 24.9 Billion JPY | 113.114% |
| Immuno-Biological Laboratories Co., Ltd. | -498.15 Million JPY | -555.702% |
| NanoCarrier Co., Ltd. | -466.34 Million JPY | -600.424% |
| Carna Biosciences, Inc. | -2.7 Billion JPY | -20.704% |
| CanBas Co., Ltd. | -1.88 Billion JPY | -72.991% |
| D. Western Therapeutics Institute, Inc. | -982.14 Million JPY | -232.58% |
| RaQualia Pharma Inc. | -3.39 Billion JPY | 3.845% |
| Chiome Bioscience Inc. | -1.03 Billion JPY | -215.731% |
| Kidswell Bio Corporation | 343.58 Million JPY | 1050.673% |
| PeptiDream Inc. | 3.29 Billion JPY | 199.223% |
| Oncolys BioPharma Inc. | -972.59 Million JPY | -235.845% |
| Ribomic Inc. | -2.09 Billion JPY | -55.562% |
| SanBio Company Limited | -3.78 Billion JPY | 13.809% |
| Healios K.K. | -2.19 Billion JPY | -49.151% |
| BrightPath Biotherapeutics Co., Ltd. | -944.85 Million JPY | -245.703% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -2.62 Billion JPY | -24.475% |
| Delta-Fly Pharma, Inc. | -1.41 Billion JPY | -130.506% |
| StemRIM | -8.41 Billion JPY | 61.16% |
| CellSource Co., Ltd. | -4.68 Billion JPY | 30.257% |
| FunPep Company Limited | -1.79 Billion JPY | -82.137% |
| Kringle Pharma, Inc. | -2.13 Billion JPY | -52.887% |
| Stella Pharma Corporation | -1.11 Billion JPY | -191.799% |
| TMS Co., Ltd. | -3.44 Billion JPY | 5.229% |
| Noile-Immune Biotech Inc. | -5.55 Billion JPY | 41.206% |
| Cuorips Inc. | -5.56 Billion JPY | 41.262% |
| Takara Bio Inc. | -32.2 Billion JPY | 89.857% |
| ReproCELL Incorporated | -2.93 Billion JPY | -11.138% |
| PhoenixBio Co., Ltd. | -660.96 Million JPY | -394.191% |
| StemCell Institute Inc. | -2.83 Billion JPY | -15.146% |
| Japan Tissue Engineering Co., Ltd. | -2.06 Billion JPY | -58.077% |
| CellSeed Inc. | -2.01 Billion JPY | -62.343% |